Overview

Effect of CAFfeine on Cognition in Alzheimer's Disease

Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
Sporadic Alzheimer's disease is a multifactorial illness arising a major medico-economic stakes for our aging societies. There is currently no curative treatment available. Coffee is a complex beverage with psychostimulant properties whose main effective element, caffeine, has a pleiotropic effect on the central nervous system. Caffeine pharmacological properties enable its use like an Alzheimer's disease symptomatic treatment. Its supposed benefits mustn't obscure anxiety and insomnia caffeine effect at large dose, which Alzheimer's patients might be more vulnerable. The main study objective is to evaluate placebo-controlled caffeine efficacy (30 treatments weeks) on cognitive decline in Alzheimer's disease dementia at beginning to moderate stage (MMSE 16-24).
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Lille
Collaborators:
Groupement Interrégional de Recherche Clinique et d'Innovation
Laboratory of excellence DISTALZ
Meo coffee
Région Nord-Pas de Calais, France
Treatments:
Caffeine